Location:Room Vienna (Hall B2, level 0)
Therapy resistance in prostate cancer develops as a result of activation of multiple signaling pathways. Understanding these mechanisms is a condition for a more efficient therapy. Several abstracts in this session will focus on experimental approaches to combat resistance.
- Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
Institutes: 1Hôpitaux Universitaires Henri Mondor, Dept. of Urology, Créteil, France, 2CNIO, Dept. of Genetic and Molecular Epidemiology, Madrid, Spain, 3Ramon Y Cajal Hospital, Dept. of Oncology, Madrid, Spain, 4Oviedo University, Dept. of Preventive Medicine, Oviedo, Spain, 5NCI, Dept. of Cancer Epidemiology and Genetics, National Cancer Institute, Department of Health and Human Services,, Bethesda, Maryland, United States of America, 6Hôpitaux Universitaires Henri Mondor, Dept. of Pathology, Créteil, France, 7CNIO, Dept. of Epithelial Carcinogenesis, Madrid, Spain